Annovis Bio Inc (DE:07X)
NYSE:07X
07X Stock Chart & Stats
€1.51
-€0.35(-6.67%)
At close: 4:00 PM EST
€1.51
-€0.35(-6.67%)
Day’s Range― - ―
52-Week Range€1.35 - €4.61
Previous CloseN/A
Volume125.00
Average Volume (3M)764.00
Market Cap
€55.48M
Enterprise Value€23.55M
Total Cash (Recent Filing)€14.22M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 18, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume222
30 Day Avg. Volume764
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.75Price Target Upside611.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Lead AssetBuntanetap in Phase 3 represents a structural strength: late-stage programs have clearer regulatory pathways and higher value creation potential than earlier assets. Successful trial outcomes could shift the company to a commercial-stage model, materially improving long-term revenue prospects and partner interest.
Debt-free Balance SheetZero reported debt provides durable financial flexibility, lowering fixed obligations and interest exposure. This improves the company’s ability to prioritize R&D spend and negotiate equity or strategic partnerships without immediate refinancing pressure, supporting longer runway management decisions.
Proven Access To CapitalRecent priced offerings demonstrate the company can source external equity to fund clinical programs, a critical structural capability for pre-revenue biotechs. Reliable capital access underpins the ability to complete Phase 3 work and preserve program continuity, reducing binary operational interruptions.
Bears Say
No Revenue / Persistent LossesZero revenues with recurring operating losses is a fundamental weakness: the business depends entirely on trial success and external funding. Without commercial sales, sustainable profitability is contingent on clinical and regulatory outcomes, increasing execution risk over the medium term.
Worsening Cash BurnDeepening and volatile negative cash flow reduces predictable runway and raises the probability of additional financings. Persistent cash consumption forces management to prioritize fundraising over optional investments, elevating dilution risk and constraining long-term strategic flexibility.
Reliance On Dilutive EquityRepeated dilutive offerings as the primary funding mechanism signal limited alternative funding sources. Structural reliance on equity enlarges share count over time, impairing per-share economics and investor returns unless clinical success justifies expansion, making shareholder value contingent on trial outcomes.
Annovis Bio News
07X FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was €1.35 and its highest was €4.61 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is €55.48M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -€0.543 earnings per share for the quarter, missing the consensus estimate of -€0.34 by -€0.202.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.4.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 34,646,870 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -€0.543 in its last earnings report, missing expectations of -€0.34. Following the earnings report the stock price went down -4.487%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in DE:07X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.75 (611.77% Upside)
€10.75 (611.77% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €1.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.54%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
07X Stock 12 Month Forecast
Average Price Target
€10.75
▲(611.77% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Options Prices
Currently, No data available
---